Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454062 | PMC |
| http://dx.doi.org/10.4274/tjh.2014.0166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
Leuk Res
January 2025
Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima, Japan. Electronic address:
The standard treatment for aggressive adult T-cell leukemia/lymphoma (ATL) is multi-agent chemotherapy, but the use of more intense cytotoxic anticancer agents is becoming more difficult with the aging of patients at the time of diagnosis. As a means of overcoming this hurdle, antibody drugs, which are supposed to be less toxic, have been developed for ATL. The advent of the anti-CC chemokine receptor 4 (CCR4) antibody mogamulizumab has significantly advanced ATL treatment.
View Article and Find Full Text PDFPractical recommendations for therapy and monitoring of mogamulizumab patients in Germany.
J Dtsch Dermatol Ges
December 2024
Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.
View Article and Find Full Text PDFSuccessful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.
JAMA Dermatol
December 2024
Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.
Int J Hematol
November 2024
Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains.
View Article and Find Full Text PDFPotential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management.
JAAD Case Rep
December 2024
Division of Dermatology and Venereology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!